EP3288585A4 - Nouvelles compositions et méthodes pour immunothérapies comprenant des adjuvants agonistes des récepteurs-ligands d'intégrine à petites molécules - Google Patents

Nouvelles compositions et méthodes pour immunothérapies comprenant des adjuvants agonistes des récepteurs-ligands d'intégrine à petites molécules Download PDF

Info

Publication number
EP3288585A4
EP3288585A4 EP16787110.2A EP16787110A EP3288585A4 EP 3288585 A4 EP3288585 A4 EP 3288585A4 EP 16787110 A EP16787110 A EP 16787110A EP 3288585 A4 EP3288585 A4 EP 3288585A4
Authority
EP
European Patent Office
Prior art keywords
inegrine
immunotherapies
methods
small molecule
novel compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP16787110.2A
Other languages
German (de)
English (en)
Other versions
EP3288585A2 (fr
Inventor
Darren G. Woodside
Peter Vanderslice
Upendra K. Marathi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
7 Hills Interests LLC
Texas Medical Center
Original Assignee
7 Hills Interests LLC
Texas Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 7 Hills Interests LLC, Texas Medical Center filed Critical 7 Hills Interests LLC
Priority claimed from PCT/US2016/029683 external-priority patent/WO2016176400A2/fr
Publication of EP3288585A2 publication Critical patent/EP3288585A2/fr
Publication of EP3288585A4 publication Critical patent/EP3288585A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP16787110.2A 2015-04-29 2016-04-28 Nouvelles compositions et méthodes pour immunothérapies comprenant des adjuvants agonistes des récepteurs-ligands d'intégrine à petites molécules Pending EP3288585A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562154554P 2015-04-29 2015-04-29
PCT/US2016/029683 WO2016176400A2 (fr) 2015-04-29 2016-04-28 Nouvelles compositions et méthodes pour immunothérapies comprenant des adjuvants agonistes des récepteurs-ligands d'intégrine à petites molécules

Publications (2)

Publication Number Publication Date
EP3288585A2 EP3288585A2 (fr) 2018-03-07
EP3288585A4 true EP3288585A4 (fr) 2019-05-01

Family

ID=61024178

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16787110.2A Pending EP3288585A4 (fr) 2015-04-29 2016-04-28 Nouvelles compositions et méthodes pour immunothérapies comprenant des adjuvants agonistes des récepteurs-ligands d'intégrine à petites molécules

Country Status (1)

Country Link
EP (1) EP3288585A4 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012068251A2 (fr) * 2010-11-16 2012-05-24 Texas Heart Institute Agonistes améliorant la liaison de cellules exprimant des intégrines à des récepteurs d'intégrines

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012068251A2 (fr) * 2010-11-16 2012-05-24 Texas Heart Institute Agonistes améliorant la liaison de cellules exprimant des intégrines à des récepteurs d'intégrines

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ALESSANDRA TOLOMELLI ET AL: "Can Integrin Agonists Have Cards to Play against Cancer? A Literature Survey of Small Molecules Integrin Activators", CANCERS, vol. 9, no. 12, 5 July 2017 (2017-07-05), pages 78, XP055531258, DOI: 10.3390/cancers9070078 *
ANDREW M. SCOTT ET AL: "Antibody therapy of cancer", NATURE REVIEWS. CANCER, vol. 12, no. 4, 1 April 2012 (2012-04-01), GB, pages 278 - 287, XP055531673, ISSN: 1474-175X, DOI: 10.1038/nrc3236 *
M. A. SCHWARTZ ET AL: "Integrin Agonists as Adjuvants in Chemotherapy for Melanoma", CLINICAL CANCER RESEARCH, vol. 14, no. 19, 1 October 2008 (2008-10-01), US, pages 6193 - 6197, XP055531739, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-08-1285 *
SIMON L GOODMAN ET AL: "Integrins as therapeutic targets", TRENDS IN PHARMACOLOGICAL SCIENCES, vol. 33, no. 7, 1 July 2012 (2012-07-01), pages 405 - 412, XP028495741, ISSN: 0165-6147, [retrieved on 20120412], DOI: 10.1016/J.TIPS.2012.04.002 *

Also Published As

Publication number Publication date
EP3288585A2 (fr) 2018-03-07

Similar Documents

Publication Publication Date Title
EP3843729A4 (fr) Nouvelles compositions et méthodes
EP3600325A4 (fr) Nouvelles compositions et méthodes
EP3589646A4 (fr) Compositions à base de cd19 et méthodes pour l'immunothérapie
EP3353278A4 (fr) Préparation d'échantillons pour des types d'échantillons compliqués
EP3446194A4 (fr) Raccourcis d'application pour carplay
EP3445407A4 (fr) Compositions et méthodes d'immunothérapie cellulaire
IL264637B (en) Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
EP3353309A4 (fr) Compositions et méthodes pour l'édition génomique
EP3905900C0 (fr) Formulation de nicotine liquide
EP3436083A4 (fr) Nouvelles compositions et méthodes
EP3423435A4 (fr) Inhibiteurs d'indoles mcl-1 substitués
FR26C1014I1 (fr) Compositions pharmaceutiques contenant de l'insuline
DK3672631T5 (da) Farmaceutiske sammensætninger indeholdende anti-beta-amyloid-antistoffer
IL255297A0 (en) Novel compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants
MA49006A (fr) Inhibiteurs d'ip6k
FR3022462B1 (fr) Composition orale d'anticorps anti-tnfalpha
MA45987A (fr) Agonistes des récepteurs 5-ht2c, compositions et méthodes d'utilisation
SI3661373T1 (sl) Farmacevtska sestava za anemijo
IL258127B (en) Phenyl derivatives as cannabinoid receptor 2 agonists
EP3530722A4 (fr) Composition d'agent nettoyant
EP3893901A4 (fr) Compositions et méthodes pour immunothérapies
EP3338870A4 (fr) Composition d'agent antimousse et d'huile lubrifiante
EP3338871A4 (fr) Agent antimousse et composition d'huile lubrifiante
EP3419988A4 (fr) Nouvelles jonctions trois voies d'arnp
EP3408731A4 (fr) Modes d'interaction pour interactions objet-dispositif

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20171113

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: 7 HILLS INTERESTS, LLC

Owner name: TEXAS HEART INSTITUTE

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/16 20060101ALI20181213BHEP

Ipc: A61K 39/39 20060101ALI20181213BHEP

Ipc: A61K 31/381 20060101ALI20181213BHEP

Ipc: A61K 39/00 20060101AFI20181213BHEP

Ipc: A61K 31/36 20060101ALI20181213BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20190401

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/36 20060101ALI20190326BHEP

Ipc: A61K 31/381 20060101ALI20190326BHEP

Ipc: A61K 39/00 20060101AFI20190326BHEP

Ipc: A61K 39/39 20060101ALI20190326BHEP

Ipc: A61K 31/16 20060101ALI20190326BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200616

R17C First examination report despatched (corrected)

Effective date: 20200717